[Featured Stock] Cellid, Holding US and Russia Patents for COVID-19 Vaccine Technology, Hits Daily Limit for Three Consecutive Days

Cellid's stock price soared to the upper limit again on the 25th. Cellid has been on a three-day streak of hitting the upper limit since the 23rd.

As of 10:47 AM on the 25th, Cellid was trading at 3,860 KRW, up 29.97% (890 KRW) from the previous trading day. Cellid also recorded the upper limit on the 23rd and 24th. Cellid is a bio-venture company developing cell-based immunotherapy vaccines and infectious disease preventive vaccines, established in a laboratory within the College of Pharmacy at Seoul National University.

On the 23rd, news that the US and Russian patent registrations were approved for the proprietary adenovirus vector platform technology applied to the COVID-19 vaccine ‘AdCLD-CoV19-1 OMI’ appeared to act as a positive factor for the stock price.

Cellid stated that with this patent registration, its self-developed vector platform technology has been recognized in the United States, and it is expected to reduce dependence on overseas technology when developing vaccines.

This content was produced with the assistance of AI translation services.